| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2575732 | The American Journal of Geriatric Pharmacotherapy | 2012 | 11 Pages |
Abstract
Treatment of CDI is challenging due to the limited number of drugs that have proven to be effective, concerns about antibiotic resistance, and recurring disease. The recent approval of fidaxomicin provides a new alternative. Immune therapy will likely play a greater role in the future.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Geriatrics and Gerontology
Authors
Vicki R. PharmD, BCPS,